CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. (Q48686872)
Jump to navigation
Jump to search
scientific article published on 2 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. |
scientific article published on 2 March 2017 |
Statements
1 reference
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. (English)
1 reference
Padmanee Sharma
David F McDermott
Saby George
Hans J Hammers
Sandhya Srinivas
Scott S Tykodi
Jeffrey A Sosman
Elizabeth R Plimack
Daniel Castellano
Katriina Peltola
Thomas C Gauler
Takeshi Ueda
Huanyu Zhao
Ian M Waxman
Robert J Motzer
CheckMate 025 investigators
Bernard Escudier
2 March 2017
1 reference